Impax Laboratories (Nasdaq: IPXL) is expected to report Q4 earnings on Feb. 25. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories's revenues will shrink -20.2% and EPS will contract -50.0%.

The average estimate for revenue is $126.6 million. On the bottom line, the average EPS estimate is $0.18.

Revenue details
 Last quarter, Impax Laboratories logged revenue of $145.6 million. GAAP reported sales were 21% higher than the prior-year quarter's $119.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.48. GAAP EPS of $0.29 for Q3 were 12% higher than the prior-year quarter's $0.26 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 53.6%, 130 basis points better than the prior-year quarter. Operating margin was 20.0%, 290 basis points worse than the prior-year quarter. Net margin was 13.8%, 60 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $575.2 million. The average EPS estimate is $1.76.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 170 members out of 183 rating the stock outperform, and 13 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Impax Laboratories a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $25.59.